Scarica l'app Stockscreener
2.22
5.93%
-0.14
Dopo l'orario di chiusura:
2.22
Precedente Chiudi:
$2.36
Aprire:
$2.35
Volume 24 ore:
35,919
Relative Volume:
0.40
Capitalizzazione di mercato:
$49.73M
Reddito:
-
Utile/perdita netta:
$-61.06M
Rapporto P/E:
-0.155
EPS:
-14.3261
Flusso di cassa netto:
$-59.30M
1 W Prestazione:
-3.06%
1M Prestazione:
-15.27%
6M Prestazione:
-32.73%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.22
$2.3948
Intervallo di 1 settimana:
$2.1492
$2.54
Portata 52W:
$2.1492
$12.65
Boundless Bio Inc Stock (BOLD) Company Profile
Nome
Boundless Bio Inc
Settore
Industria
Telefono
(858) 766-9912
Indirizzo
9880 CAMPUS POINT DRIVE, SAN DIEGO
Confronta BOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
2.22 | 49.73M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-22 | Iniziato | Guggenheim | Buy |
| 2024-04-22 | Iniziato | Leerink Partners | Outperform |
| 2024-04-22 | Iniziato | Piper Sandler | Overweight |
Boundless Bio Inc Borsa (BOLD) Ultime notizie
Francisco Ballester to retire from Sandoz - BioCentury
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer -February 03, 2025 at 10:00 am EST - Marketscreener.com
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Beta Bionics targets IPO of up to $120M - BioWorld Online
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer - BioSpace
Neomorph Appoints Dr. Klaus Wagner as Chief Medical Officer - citybiz
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation - Simply Wall St
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy - MSN
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development - Business Wire
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Layoffs Continued Across Biopharma in 2024 - BioSpace
The Escalator: Boundless Bio, Intelliguard, Klick Health and more - MM+M Online
Guggenheim Downgrades Boundless Bio (BOLD) - MSN
Boundless Bio Announces Pipeline and Leadership Updates - The Manila Times
Genesis hires Shifeng Pan as CSO, names Paul Friedman chair - BioCentury
Boundless Bio, Inc. Changes to Management Team - Marketscreener.com
Boundless Bio Won't Advance Cancer Treatment Trial, Executives to Step Down - MarketWatch
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Amgen names Howard Chang head of research and CSO - BioCentury
S&P 500 Consumer Staples [Sector] (SRCS) QuotePress Release - The Globe and Mail
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
Science Spotlight: How extrachromosomal DNA drives cancer - BioCentury
Extrachromosomal DNA acts as joker for cancer cells - BioWorld Online
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Stanford Scientists Overturn Mendel’s Law With Shocking Cancer Discovery - SciTechDaily
Stanford researchers unveil the key role of extrachromosomal DNA in cancer - News-Medical.Net
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - The Manila Times
Boundless Bio Prices IPO At $16/Shr - RTTNews
Boundless Bio CFO Jami Rubin steps down By Investing.com - Investing.com Australia
Boundless Bio CFO Jami Rubin Steps Down for Personal Reasons - MarketWatch
Boundless Bio CFO Jami Rubin steps down - Investing.com
Boundless Bio Announces Departure of Chief Financial Officer - The Bakersfield Californian
Ceribell begins trading with upsized IPO - BioWorld Online
Down rounds don’t aid post-IPO performance - BioCentury
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - Yahoo Finance
Varun Dhawan's niece Anjini Dhawan's debut film Binny and Family release postponed - India Today
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - GlobeNewswire
Limitless Labs Secures $3M Pre-Seed Funding Led by 1confirmation - iGaming.org
FDA Grants Breakthrough Status to Achondroplasia Drug By Investing.com - Investing.com Canada
Limitless Labs Secures $3M in Pre-Seed Funding Led by 1confirmation - Blockster
A New Prediction Market Raises $3M in Pre-Seed Round Led by 1confirmation - CoinDesk
'Binny And Family' pushed again; to now release on this date - NewsBytes
The War On Drugs On Beyoncé Collaboration: 'It’s Arguably The Coolest Thing I’ve Ever Done' - Dig!
Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer - Medical Xpress
Boundless Bio Inc Azioni (BOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Boundless Bio Inc Azioni (BOLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CRANDELL KEITH | 10% Owner |
Apr 02 '24 |
Buy |
16.00 |
200,000 |
3,200,000 |
1,181,766 |
| ARCH Venture Fund IX, L.P. | 10% Owner |
Apr 02 '24 |
Buy |
16.00 |
200,000 |
3,200,000 |
1,181,766 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Apr 02 '24 |
Buy |
16.00 |
312,500 |
5,000,000 |
1,884,787 |
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):